Navigation Links
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
Date:6/1/2009

so presented(3) . Fifty-six patients were enrolled with daily oral doses of AT-101 given for 21 of 28 days in repeated cycles. The treatment was well tolerated, with a low incidence of serious adverse events and no unique central nervous system toxicities. Responses were evaluated in 43 patients and included one confirmed partial response and 8 patients with stable disease, representing half of the patients still alive at the time of analysis. Progression-free survival (PFS) in these patients ranged from 8 to 13 months. Determination of the impact of AT-101 on overall survival (OS), the primary endpoint, is ongoing.

AT-101 in Lung Cancer

Reports from two studies in lung cancer also showed promising signals of antitumor effect. The first presentation described results from a randomized, double-blind, placebo-controlled Phase II trial in 105 patients who had received one prior chemotherapy regimen for non-small cell lung cancer (NSCLC)(4). While the primary endpoint, a statistically significant improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the docetaxel plus placebo arm. Common adverse events included fatigue (18 percent), anemia (18 percent) and dyspnea (18 percent). Using NSCLC cell lines, a genomic profile predicting response to AT-101 was developed in collaboration with Duke University. Opportunities to validate this biomarker will be pursued in future trials.

The second presentation reported on an open-label, Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer (SCLC) who had received prior platinum-based first line chemotherapy(5). The Phase II portion of the trial included 25 patients div
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... SAIC-Frederick, Inc. and Biomatrica have begun ... which is becoming increasingly important in cancer research and ... therapies. The two organizations will focus on ... samples collected by pathologists in the clinic. Preserving nucleic ...
... be a magnet, and how can we control a magnet,s ... Igor Zutic, a theoretical physicist, has been exploring over many ... that magnets could revolutionize computing, forming the basis of high-capacity ... Today, in a commentary in Science , Zutic and ...
... Calif., May 26, 2011 MAP Pharmaceuticals, ... it has submitted a New Drug Application (NDA) to ... LEVADEX® orally inhaled migraine drug for the potential acute ... Headache Foundation, approximately 30 million people in the United ...
Cached Biology Technology:SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research 2SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research 3Chameleon magnets: Ability to switch magnets 'on' or 'off' could revolutionize computing 2Chameleon magnets: Ability to switch magnets 'on' or 'off' could revolutionize computing 3MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 2MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 3MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 4
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... The increased risk of kidney injury related to the ... the mass of HES molecules, according to a report ... the International Anesthesia Research Society (IARS). , The "total ... HES on cultured human renal proximal tubule cells (PTCs), ... colleagues of University Hospital Wrzburg, Austria. Other factorssuch ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... public divided about climate change because they don,t understand ... science and were more proficient in technical reasoning, would ... today online in the journal Nature Climate Change ... no. Indeed, as members of the public become more ...
... (RBC) is a critical component in the treatment ... problems. Indeed, approximately 75 million units of whole ... for processing and eventual transfusion. Despite this massive ... availability due to a combination of collection, manufacturing, ...
... the healthy growth of coral reefs in Hawaii may ... day treat human diseases, a new study led by ... Diego has revealed. An analysis led by Hyukjae ... Scripps, has shown that the seaweed, a tiny photosynthetic ...
Cached Biology News:Yale study concludes public apathy over climate change unrelated to science literacy 2Proteomic analysis of immunocamouflaged surfaces 2Nuisance seaweed found to produce compounds with biomedical potential 2
... from BRAND adds ergonomics and ease-of-use ... only electronic, motor-driven repeating pipette compatible ... BRAND PD-Tip syringe tips, Eppendorf Combi-Tips ... VWRbrand Combi-Syringes. Select virtually any pipetting ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
Biology Products: